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Summary
Introduction: Vagus nerve stimulation (VNS) is thought to have a cumulative effect in
time on seizure frequency reduction. There also might be other variables than
reduction of seizure frequency in order to determine VNS efficacy. In this study
we describe the long-term outcome of the first group of vagus nerve stimulation
patients with pharmacoresistant epilepsy at the Medisch Spectrum Twente, The
Netherlands.
Methods: This long-term descriptive prospective study included 19 patients, 11
males and 8 females, aged 17—46 years with pharmacoresistant epilepsy. They
had received 3—16 (mean 9) different anti-epileptic drugs and were not eligible
for surgical resection of an epileptic focus. Avagus nerve stimulator was implanted in
the period April 1999—October 2001. Follow-up ranges from 2 to 6 years (mean 4
years). Efficacy was measured as the percentage change in seizure rate during 1 year
and then after each year follow-up of VNS compared to 5 months baseline before
implantation.
Results: Mean seizure reduction at 1—6 years was, respectively, 14% (n = 19), 25%
(n = 19), 29% (n = 16), 29% (n = 15), 43% (n = 9) and 50% (n = 7). Because of VNS two
patients were able to start living without supervision. One patient died after 2 years
of follow-up possibly as a result of SUDEP. Four patients had no apparent reduction in
seizure frequency. Two of them had their stimulator removed. The other two
patients however had significantly reduced post-ictal periods and seizure time
and received a new pulse generator when the battery was depleted. One stimulator
was switched off due to adverse effects, even though there was a positive effect on
his seizure reduction. In six patients the medication regimen was changed during
VNS by adding one anti-epileptic drug, however without significant change in seizure* Corresponding author. Tel.: +31 53 487 2850; fax: +31 53 487 2882.
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reduction. Adverse effects were hoarseness and coughing during stimulation. One
patient had a temporary paralysis of his left vocal cord.
Conclusion: We think that VNS is an effective treatment for pharmacoresistant
epilepsy and its positive effect persists during the years of follow-up. Our results
suggest that seizure reduction should not be considered as the only variable of
importance to describe the outcome of VNS on epilepsy and it is worthwhile to look
at other outcome measures.
# 2007 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.Introduction
Early studies indicated that vagus nerve stimulation
(VNS), used for medically refractory epilepsy, might
have a cumulative effect in time on seizure fre-
quency reduction.1—3 In addition, a number of long-
term VNS outcome studies reported an improved
effect in seizure reduction over a period of time.4—7
Furthermore, studies suggest other variables than
reduction of seizure frequency to describe VNS
efficacy, such as reduced post-ictal period, reduced
seizure severity or an improved quality of life.4,8
Evaluating VNS outcome is important because about
30% of patients with epilepsy have medically refrac-
tory epilepsy or have unacceptable side-effects
from their anti-epileptic drug regimen at therapeu-
tic dosage. Some of them will benefit from resective
surgery.9 For those who are not eligible for epileptic
focus resection, VNS-therapy has been shown to be
an effective alternative.
In response to the clinical outcome studies in
the European community and the United States,
VNS was introduced in our centre in 1999 as an
add-on therapy for patients with medically refrac-
tory epilepsy. The primary objective of this study
was to determine seizure frequency reduction in a
long-term study in patients receiving VNS. Sec-
ondly, we investigated whether other relevant
outcome measures could be identified in order
to determine the effectiveness of VNS. We
describe the experience in 19 patients in a long-
term prospective study in a single centre in a
period of up to 6 years.Methods
Patient population
From April 1999 to October 2001, 19 patients with
medically refractory epilepsy received a VNS system
at Medisch Spectrum Twente Hospital, Enschede.
There were 11 males and 8 females, with an average
age of 33 years at the time of implantation. All had
partial seizures. The average age at epilepsy onset
was 11 years. Patients had a mean duration ofrefractory epilepsy of 23 years before VNS, and
had received an average of 9 different anti-epileptic
drugs. The average number of seizures before VNS
was 28 per month (measured prospectively from
baseline at 5 months before the implantation). None
of them were eligible for surgical resection of an
epileptic focus. Patients’ characteristics are given
in Table 1.
Study design
The primary objective was to study the outcome on
seizure frequency of patients receiving VNS over a
long-term period. In this long-term prospective ana-
lysis of patients, a VNS system (Cyberonics, Hous-
ton, TX, US) was implanted in patients between
April 1999 and October 2001. We retrieved epilepsy
seizure charts from November 1998 to September
2006. During the study period, all seizures were
counted at the end of each year follow-up after
implantation, and seizure frequency per month was
then calculated. Clustering of seizures was counted
as one seizure. Primary efficacy was defined as the
percentage change in total seizure frequency for
each year of follow-up compared to the seizure
frequency per month from 5 months baseline. Ten
days postoperative VNS-therapy was initiated. Gra-
dual current ramp-up was done with steps of
0.25 mA every 3—4 weeks, according to tolerance
of side effects. The first 3 months of VNS were
excluded from analysis, because during this period
the stimulator parameters had not reached settings
which are believed to be therapeutic. Thus, efficacy
over the first year was calculated over the last 9
months. During the total period of follow-up, sti-
mulator parameters could be changed in order to
reach the best optimal therapy for each individual
patient. Furthermore, we retrospectively evaluated
whether there was a change in seizure type, when
patients reported different types of seizures. We
also evaluated whether seizure reduction outcome
is related to the length of medically refractory
epilepsy period or the age of epilepsy onset and
starting VNS. Retrospectively we also evaluated
whether there was an increase in days without
seizures per month.
Vagu
s
n
e
rve
stim
u
la
tio
n
fo
r
m
e
d
ica
lly
re
fra
cto
ry
e
p
ile
p
sy
581
Table 1 Patients’ characteristics
Patient Sex Age at onset
epilepsy
(years)
Etiology Seizure type MRI findings Number
of AEDs
Years of
epilepsy
before VNS
Age at onset
VNS (years)
Seizure frequency
before VNS
(per month)
1 M 14 Perinatal anoxia CPS + aura Normal 14 33 46 9
2 M 13 Head trauma SPS + SGTC Hyperintensity
temporal left
7 10 23 2
3 M 1 Ischemia right
medial artery
SPS Ischemia right
medial artery
8 24 25 21
4 M 1 Polio encephalitis CPS + aura Cortical dysplasia
left fronto-parietal
10 40 41 6
5 F 14 Unknown CPS + GTC Normal 8 11 25 22
6 F 4 Arachnoid cyste CPS + SGTC Arachnoid cyste
temporal right
7 26 30 45
7 M 6 Unknown SPS Normal 6 39 45 139
8 F 27 Unknown CPS Normal 3 11 38 7
9 F 5 Unknown CPS + SGTC Left temporal
loss of tissue
12 23 28 21
10 F 13 Meningitis SPS + SGTC Left frontal gliosis 8 29 38 9
11 M 8 Encephalitis SPS + CPS + SGTC Normal 12 9 17 12
12 F 11 Unknown GTC Normal 16 25 40 58
13 F 13 Cortical dysplasia CPS Cortical dysplasia
insula
9 23 36 17
14 F 26 Unknown CPS + GTC Normal 10 15 41 25
15 M 5 Haemolytic
uremic syndrome
CPS Multiple gliosis 7 20 25 10
16 M 10 Unknown SPS Normal 14 20 30 94
17 M 6 Meningitis CPS Atrophia right
fronto-temporal
8 22 28 14
18 M 4 Unknown SPS Normal 9 36 40 3
19 M 26 Unknown SPS + CPS Atrophia right occipital 8 11 37 20
M: male, F: female, SPS: simple partial, CPS: complex partial, SGTC: secondary generalised tonic clonic, AED: anti-epileptic drug.
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Figure 1 Seizure reduction over 6 years follow-up. The
percentage seizures compared to 5 months baseline. The
95% confidence interval is integrated in the figure.Our secondary objective was to evaluate whether
there are other outcome variables to describe VNS
efficacy. These second outcome variables were col-
lected through retrospective record review. When
patients came for periodic hospital visits, patients
and caregivers were frequently asked to describe
the effect of VNS on seizure severity and post-ictal
period recovery. In addition, they were asked to
evaluate the use of additional magnet activation on
epilepsy pattern. Moreover, they were asked to
report VNS related side effects, and to describe
changes in the quality of life such as social, work
or home related aspects.
During the first year of VNS patients had a stable
anti-epileptic drug regimen. Thereafter medication
adjustments were permitted. During the period of
medication adjustments of VNS parameters did not
change for several months in order to evaluate the
effect of medication changes only.
For statistical analysis of this longitudinal data
we used repeated measurements analysis (mixed
models in SPSS 14.0). This analysis technique takes
into account the correlation between intra-indivi-
dual measures. It estimates what patients did in
their years of follow-up and estimates their values in
the future. For each year of follow-up, the fre-
quency of seizures was calculated as a percentage
of baseline. These percentages were entered into
the repeated measurements analysis. The default
value for the baseline visit is 100%, data outcome is
statistical significant when the upper limit of the
confidence intervals drops below 100%.
The study was approved by our Medical Ethical
Board, and was not part of a sponsored clinical trial,
nor were the authors connected with industry.Results
Efficacy
Mean follow-up was 4 years (range 2—6 years).
There were 23 VNS devices implanted. Four devices
were replaced due to end of battery-life (all model
100 stimulators).
Mean device parameters during the years of fol-
low-up were as follows: current output 1.50 mA,
stimulation frequency, 30 Hz; pulse width, 250 ms;
signal on time, 30 s; signal off time, 3 min. Mean
magnet settings were as follows: current output
1.75 mA, pulse width 250 ms, and on-time 60 s.
Mean seizure reduction after 1—6 years was,
respectively, 14% (n = 19), 25% (n = 19), 29% (n =
16), 29% (n = 15), 43% (n = 9) and 50% (n = 7). This
is presented in Fig. 1. It shows that the reduction in
the first year is not statistical significant, becausethe upper limit of the 95% confidence interval is
100%. Nevertheless, the positive effect of VNS per-
sists during the years of follow-up, seizure fre-
quency is decreasing and is becoming more
significant as shown with the 95% confidence inter-
val. A  50% seizure reduction was achieved in 12%,
33%, 31%, 36%, 38%, and 25% of patients at, respec-
tively, 1—6 years of VNS. Six responders had an
ongoing improvement in seizure reduction during
their entire follow-up. One patient became seizure
free. Three responders experienced an initial effect
that gradually diminished after 2—3 years. There
were four patients without any seizure frequency
reduction. In fact, two of them experienced a mild
increase in seizure frequency.
From eight patients we received seizure fre-
quency charts differentiated to different types of
seizures. There was no significant change in seizure
type, only a general frequency reduction. We found
no relation between the length of medically refrac-
tory epilepsy period before starting with VSN or the
age of epilepsy onset and seizure reduction. There
was no significant increase in seizure free days per
month.
Eleven patients stayed on a stable anti-epileptic
drug regimen. One patient stopped using topira-
mate when his seizure frequency was reduced by
50%, and remained stable in the follow-up. Another
patient with 75% seizure frequency reduction after 1
year experienced a mild but gradual diminishing
effect of VNS. After 5 years, when seizure frequency
reduction was 58%, pregabaline was added. After 6
months, when seizure frequency did not change
much, VNS was turned to the rapid cycle (7 s on,
18 s off) and the seizure frequency was reduced to
87%. Two patients started levetiracetam after 2 and
3 years of VNS. During a 6months follow-up period in
both patients no obvious decrease in seizure fre-
quency were noticed. One patient, with an initial
effect of 37% seizure reduction with VNS, started
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Table 2 Side effects of vagus nerve stimulation
Side effects Percentage
Hoarseness 84
Coughing 32
Paresthesia 16
Dyspnea on exertion 16
Pain 16
Paralysis vocal cord 11oxcarbamazepine after 3 years of VNS, when sei-
zures became more frequent. However, this had no
effect on her epilepsy.
Side effects and serious adverse events
Main side effects were hoarseness (84%) and cough-
ing (32%) during the stimulation ‘‘on’’ period or
during the ‘‘on’’ period after additional magnet
activation. An overview of the recorded side effects
is given in Table 2. These side effects only occurred
during the ‘‘on’’ period of stimulation. One patient
had his stimulator temporarily switched off for 6
months, because of intolerable hoarseness and par-
esthesia during stimulation. One other patient used
the magnet to halt VNS for limited periods of time
during jogging, because of dyspnea on exertion
during the ‘‘on’’ period of stimulation.
Few serious adverse events were recorded. Two
patients experienced an intra-operatively paroxys-
mal bradycardia during device diagnostics (lead-
test). At postoperative follow-up this was not
recorded again. One patient experienced occasion-
ally a choking sensation at which time the stimula-
tion had to be discontinued for some weeks. During
those ‘‘off’’-periods his seizure frequency increased
to about one-third.
One patient had a temporary paralysis of his left
vocal cord post-operatively, that was probably
related to manipulation of the vagus nerve during
surgery. After 6 months this paralysis had recovered
spontaneously and VNS stimulation was initiated.
Afterwards he experienced no further voice altera-
tions due to VNS.
Deaths and discontinuations
During the study period five patients left the study.
One patient who had a mild reduction in seizure
frequency, died after 2 years of follow-up possibly
as a result of SUDEP. The relationship of SUDEP and
VNS in this patient is unknown. Two patients had
their stimulator system removed on their request
after, respectively, 2 and 6 years of VNS, because of
a lack of effect on their epilepsy. Two patients were
lost to follow-up. One moved to another part of thecountry, after 3 years of VNS. Another patient
stopped using his seizure calendar after 2 years.
Both are still using VNS.
Patients’ evaluation of vagus nerve
stimulation
In addition to a reduction in seizure frequency 9 out
of 19 patients (47%) reported a reduction in seizure
severity and post-ictal period. Of the earlier men-
tioned four patients without any seizure frequency
reduction, two patients claimed to have a signifi-
cantly reduced seizure severity and reduced post-
ictal periods and therefore received a new pulse
generator when the battery was depleted. One of
these two was a patient with an increase in seizure
frequency.
More than 50% of the patients and caregivers
reported that magnet activation of the VNS system
prevented the onset of a seizure or aborted a sei-
zure. Some patients were able to activate the
device with use of the magnet by themselves when
having an aura. In other patients caregivers used the
magnet to activate an extra magnet stimulation
cycle in order to abort a seizure.
Two patients said that they were able to start
living independently with the aid of VNS. Those two
patients were in their mid-thirties and still living
with their parents when VNS started. Before VNS
they had many seizures, which were often so severe
that they needed medical attention after falling, so
it was not safe to live independently. During VNS
seizure frequency and severity reduction was so
impressive in these two patients that it became safe
for them to start living alone. For the same reason
two other patients were able to start working. Four
patients felt more alert with VNS and in addition
reported positive effects on their mood.Discussion
In our study there was a gradual but significant
reduction in seizures during 6 years of VNS. The
overall effect of VNS on seizure frequency reduction
amounted to about 50% after 5 years. We found that
in almost half of the patients VNS also has a positive
effect on seizure severity, seizure duration and post-
ictal period time. There was no relation between
seizure reduction and refractory epilepsy period or
the age at onset of epilepsy.
Theoverall seizure reduction inour group is similar
to that reported by others.4,5,10 There is a possible
correlation between the duration of VNS period and
the effect on seizure reduction, as demonstrated by
others.3—5,11 Most of our responders had a gradual,
584 J.J. Ardesch et al.statistical significant improvement in seizure reduc-
tion over time. We found that patients could gradu-
ally reach a seizure frequency reduction ofmore than
50%, even after 2 years of VNS. Two patients had an
initial effect that gradually diminished in time.This is
also reported in a Norwegian study.7
There have been reports that show a significant
seizure reduction in the first 3 months.12,13 How-
ever, for our analysis we excluded the first 3 months
of VNS, because our ramp-up period was longer, in
contrast to other studies.5,6,12 Hence, our results
cannot confirm the conclusion of Salinsky et al.13
who stated that the first 3 months might be an
indicator for responders versus non-responders.
Our population is small and only 7 out of 19 have
reached 6 years of follow-up, results should there-
fore be interpreted with caution. However, in our
group there are only two discontinuations due to
lack of efficacy (11% at 4 years on average), one of
which was after 6 years of VNS. This shows a high
compliance of our patients to VNS. Uthman et al.5
describe a large population with 12 year follow-up.
They had a discontinuation of 44% at 1.9 years on
average. In that study most patients discontinued at
depletion of battery, because of lack of efficacy in
seizure reduction.
In our study, two patients who had no seizure
reduction at all, received a new stimulator when the
battery was depleted. They reported a reduced
seizure severity and reduced post-ictal period.
Furthermore, patients reported a better quality
of life with the aid of VNS. This was also reported
by Nakken et al.7 In their study of 47 patients, there
were two non-responders and five mild responders
who claimed to have a better quality of life.
When asking patients to rate their quality of life
with respect to work, social events and health we
found encouraging results, especially in patients
who were non- or mild-responders. Our results are
descriptive, in contrast to Morrow et al.,10 who used
the Rank Health Scale, and reported no effect on
quality of life. However, Dodrill and Morris14
described a better quality of life using the Quality
of Life in Epilepsy Inventory (QOLIE)-31.
We realise the limitations in our study in inter-
preting the patients’ evaluation, because this was
not done with standard questioners. However, we
value our patients’ own thoughts and experiences
on VNS and their decision to continue or discontinue
VNS. Therefore, we believe that seizure reduction
should not be the only variable to measure outcome
results, and thus agree with Schachter8 and Spanaki
et al.4 who also suggest evaluating for other out-
come standards. The effects of VNS on quality of life
are currently being studied in more detail in a large
Dutch study.Main side effects were hoarseness and coughing
during stimulation ‘‘on’’ period. These findings are
similar to others.3,15,16 No serious adverse events
were seen, although there were two patients with
intra-operative transient bradycardia. Although
one patient died of SUDEP we believe that VNS is
a safe therapy over a long period, even up to 6
years.
In conclusion, VNS is an effective long-term ther-
apy to control a patients’ seizure frequency. This
positive effect persists during the years of follow-
up. It also appears to be effective on seizure sever-
ity and post-ictal time. Our results suggest that
seizure reduction should not be considered as the
only variable of importance to describe the outcome
of VNS on epilepsy and it is worthwhile to look at
other outcome measures. A careful evaluation
about termination of VNS should be considered
because its effects gradually increase over some
years, not only on seizure reduction but also on
epilepsy in general.Acknowledgements
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